Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1990 1
1992 2
1993 2
1994 2
1995 4
1996 1
1997 1
1998 2
1999 5
2000 1
2001 7
2002 3
2003 1
2004 3
2005 2
2006 3
2007 6
2008 2
2009 2
2010 2
2011 2
2012 1
2013 3
2014 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

58 results
Results by year
Filters applied: . Clear all
Page 1
Managing the challenge of chemically reactive metabolites in drug development.
Park BK, Boobis A, Clarke S, Goldring CE, Jones D, Kenna JG, Lambert C, Laverty HG, Naisbitt DJ, Nelson S, Nicoll-Griffith DA, Obach RS, Routledge P, Smith DA, Tweedie DJ, Vermeulen N, Williams DP, Wilson ID, Baillie TA. Park BK, et al. Among authors: nicoll griffith da. Nat Rev Drug Discov. 2011 Apr;10(4):292-306. doi: 10.1038/nrd3408. Nat Rev Drug Discov. 2011. PMID: 21455238 Review.
Design, synthesis, and evaluation of prodrugs of ertapenem.
Singh SB, Rindgen D, Bradley P, Cama L, Sun W, Hafey MJ, Suzuki T, Wang N, Wu H, Zhang B, Wang L, Ji C, Yu H, Soll R, Olsen DB, Meinke PT, Nicoll-Griffith DA. Singh SB, et al. Among authors: nicoll griffith da. ACS Med Chem Lett. 2013 Jul 3;4(8):715-9. doi: 10.1021/ml400092n. eCollection 2013 Aug 8. ACS Med Chem Lett. 2013. PMID: 24900737 Free PMC article.
Reversible cysteine protease inhibitors show promise for a Chagas disease cure.
Ndao M, Beaulieu C, Black WC, Isabel E, Vasquez-Camargo F, Nath-Chowdhury M, Massé F, Mellon C, Methot N, Nicoll-Griffith DA. Ndao M, et al. Among authors: nicoll griffith da. Antimicrob Agents Chemother. 2014;58(2):1167-78. doi: 10.1128/AAC.01855-13. Epub 2013 Dec 9. Antimicrob Agents Chemother. 2014. PMID: 24323474 Free PMC article.
Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.
Lacombe P, Chauret N, Claveau D, Day S, Deschênes D, Dubé D, Gallant M, Girard Y, Huang Z, Laliberté F, Lévesque JF, Liu S, Macdonald D, Mancini JA, Masson P, Nicholson DW, Nicoll-Griffith DA, Salem M, Styhler A, Young RN. Lacombe P, et al. Among authors: nicoll griffith da. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5266-9. doi: 10.1016/j.bmcl.2009.03.105. Epub 2009 Mar 26. Bioorg Med Chem Lett. 2009. PMID: 19640717
The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.
Isabel E, Bateman KP, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, Gauthier JY, Lamontagne S, Lau CK, Léger S, LeRiche T, Lévesque JF, Li CS, Massé F, McKay DJ, Mellon C, Nicoll-Griffith DA, Oballa RM, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Thérien M, Truong VL, Wesolowski G, Young RN, Zamboni R, Black WC. Isabel E, et al. Among authors: nicoll griffith da. Bioorg Med Chem Lett. 2010 Feb 1;20(3):887-92. doi: 10.1016/j.bmcl.2009.12.083. Epub 2009 Dec 28. Bioorg Med Chem Lett. 2010. PMID: 20061146
Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans.
Gibson CR, Lu P, Maciolek C, Wudarski C, Barter Z, Rowland-Yeo K, Stroh M, Lai E, Nicoll-Griffith DA. Gibson CR, et al. Among authors: nicoll griffith da. Xenobiotica. 2013 Dec;43(12):1027-36. doi: 10.3109/00498254.2013.791761. Epub 2013 May 3. Xenobiotica. 2013. PMID: 23641955 Clinical Trial.
58 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page